PROCEPT BioRobotics (NASDAQ:PRCT) Cut to Neutral at UBS Group

UBS Group lowered shares of PROCEPT BioRobotics (NASDAQ:PRCT) from a buy rating to a neutral rating in a research note published on Tuesday morning, Marketbeat Ratings reports. They currently have $20.00 price objective on the stock.

Other analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Leerink Partners cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. Citigroup lowered shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th. Finally, Evercore assumed coverage on PROCEPT BioRobotics in a research report on Wednesday, June 24th. They set an “outperform” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $33.45.

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $18.00 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -9.89 and a beta of 0.87. PROCEPT BioRobotics has a 1 year low of $16.67 and a 1 year high of $51.38. The stock’s fifty day moving average is $22.60 and its two-hundred day moving average is $25.24.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $80.52 million. During the same period last year, the firm posted ($0.45) EPS. The business’s revenue was up 20.1% compared to the same quarter last year. On average, research analysts predict that PROCEPT BioRobotics will post -1.53 EPS for the current year.

Institutional Trading of PROCEPT BioRobotics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares during the period. Versant Capital Management Inc boosted its position in shares of PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after purchasing an additional 1,084 shares in the last quarter. Center for Financial Planning Inc. acquired a new position in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $40,000. US Bancorp DE grew its stake in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after purchasing an additional 1,079 shares during the last quarter. Finally, Cache Advisors LLC bought a new stake in shares of PROCEPT BioRobotics in the 1st quarter worth approximately $42,000. Institutional investors own 89.46% of the company’s stock.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action covering investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. The allegations center on repeated late-quarter bulk discounts for handpieces, excess customer inventory, and sales being pulled forward, potentially overstating recurring revenue trends. PROCEPT BioRobotics Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The litigation claims that management did not adequately disclose the handpiece-to-procedure differential and attributed revenue volatility to temporary saline shortages rather than inventory overstocking. These accusations raise potential legal costs, reputational risk, and uncertainty over the sustainability of PROCEPT’s sales growth. Levi & Korsinsky PROCEPT Investor Alert
• Negative Sentiment: UBS reportedly lowered its rating on PROCEPT to Neutral, adding to investor caution after concerns about discounting, inventory levels, and demand timing. PROCEPT Rating Lowered to Neutral at UBS
• Neutral Sentiment: Investors have until September 22, 2026, to seek lead-plaintiff status in the lawsuit. The deadline itself does not establish wrongdoing, but continued legal-firm notices are keeping the allegations prominent and may contribute to volatility. PROCEPT Shareholder Alert and Lead Plaintiff Deadline

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.